Simanjuntak, Destrina Grace and Tjandrawinata, Raymond R. (2011): A study on influencers of total sales revenue of generic pharmaceutical companies in Indonesia.
Download (157kB) | Preview
This paper empirically examines the influence of firms’ one-year lagged of total new products (t-1), one-year lagged profitability (t-1), and market share of new products to firms’ amount of sales revenue in pharmaceutical generic companies in Indonesia. The data used in this study was panel dataset, gathered from six large pharmaceutical generic companies in Indonesia, during the period 2006 to 2010. The regression analysis method uses fixed effect models, with generalized least squares (GLS) method. The result shows that firms’ one-year lagged of total new product (t-1), one-year lagged profitability (t-1), and market share of new products to be positive and affect significantly the firms’ sales revenue in the pharmaceutical generic companies in Indonesia.
|Item Type:||MPRA Paper|
|Original Title:||A study on influencers of total sales revenue of generic pharmaceutical companies in Indonesia|
|English Title:||A study on influencers of total sales revenue of generic pharmaceutical companies in Indonesia|
|Keywords:||Pharmaceutical Generic Companies, Profitability, New Generic Product, Market Share, Sales Revenue|
|Subjects:||L - Industrial Organization > L2 - Firm Objectives, Organization, and Behavior > L21 - Business Objectives of the Firm
C - Mathematical and Quantitative Methods > C2 - Single Equation Models ; Single Variables > C23 - Panel Data Models ; Spatio-temporal Models
A - General Economics and Teaching > A1 - General Economics > A10 - General
G - Financial Economics > G3 - Corporate Finance and Governance > G30 - General
M - Business Administration and Business Economics ; Marketing ; Accounting ; Personnel Economics > M2 - Business Economics > M21 - Business Economics
|Depositing User:||Destrina Grace Simanjuntak|
|Date Deposited:||17. Jun 2011 11:44|
|Last Modified:||17. May 2015 05:07|
A Congressional Budget Office Study, 2006, Research and Development in the Pharmaceutical Industry, Congress of The United States, Congressional Budget Office.
Brekke, Kurt R., Tor Helge Holmas, and Odd Rune Straume, 2007, Regulation, Generic Competition and Pharmaceutical Prices: Theory and Evidence from a Natural Experiment, Department of Economics and Health Economics Bergen, Norwegian School of Economics and Business Administration, Bergen, Norway.
Chen, Yu-Shan, Ke-Chiun Chang, and Mei-Hui Lin, 2006, Exploring the Nonlinear Influences of Size, Profitability and Employee Productivity upon Patent Citations in the US Pharmaceutical Industry by Using Artificial Neural Network, Department of Business Administration, National Yunlin University of Science & Technology, Taiwan.
Gujarati, Damodar, 2003. Basic Econometrics, 4th Edition (McGraw-Hill).
Moreno-Torres, Ivan, Jaume Puig-Junoy, and Joan-Ramon Borrell-Arque, 2007, Generic Entry Into a Regulated Pharmaceutical Market, Research Centre for Economics and Health and Research Group on Public Polices and Economic Regulation, Universitat de Barcelona, Barcelona, Spain.
PT. Darya Varia Laboratoria Tbk and Subsidiaries, 2006-2010, Consolidated Financial Statements, Indonesia.
PT. Indofarma (Persero) Tbk and Its Subsidiaries, 2006-2010, Consolidated Financial Statements, Indonesia.
PT. Kalbe Farma Tbk. and Subsidiaries, 2006-2010, Consolidated Financial Statements with Independen Auditors’ Report, Indonesia.
PT. Kimia Farma (Persero) Tbk, 2006-2010, Consolidated Financial Statements with Independen Auditors’ Report, Indonesia.
PT. Pyridam Farma Tbk, 2006-2010, Consolidated Financial Statements with Independen Auditors’ Report, Indonesia.
PT. Tempo Scan Pacific Tbk and Subsidiaries, 2006-2010, Consolidated Financial Statements with Independen Auditors’ Report, Indonesia.
Reiffen, David and Michael R. Ward, 2002, Generic Drug Industry Dynamics, US Treasury Department, and University of Illinois and University of Texas at Arlington.
Scherer, F.M., 2001, The Link between Gross Profitability and Pharmaceutical Spending, Health Affairs 20(5), pp. 216-220.
Simanjuntak, Destrina Grace and Raymond R. Tjandrawinata, 2011, Impact of Profitability, R&D Intensity, and Cash Flow on R&D Expenditure in Pharmaceutical Companies, Department of Business Development, Dexa Medica Group, Jakarta, Indonesia.
Stremersch, Stefan and Aurelie Lemmens, 2008, Sales Growth of New Pharmaceuticals Across the Globe: The Role of Regulatory Regimes, Erasmus Research Institute of Management (ERIM), RSM Erasmus University/Erasmus School of Economics, Erasmus Universiteit Rotterdam, The Netherlands.
Vernon, Jhon A., 2004, Examining the Link between Price Regulation and Pharmaceutical R&D Investment, Economics of the Pharmaceutical Industry, Wiley InterScience.
Vernon, John A., Joseph H. Golec, Randal Lutter, and Clark Nardinelli, 2006, FDA New Drug User Fees, and R&D Spending, AEI-Brooking Joint Center For Regulatory Studies Working Paper 06-21.